BridgeBio Oncology Therapeutics (BBOT) Investment Gain (Loss) (2024 - 2025)
BridgeBio Oncology Therapeutics (BBOT) posted Investment Gain (Loss) of $1159.0 for Q2 2025, down 52.6% sequentially from $2445.0 in Q1 2025.
Powered by 
Analysis
BridgeBio Oncology Therapeutics (BBOT) Investment Gain (Loss) (2024 - 2025) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Investment Gain (Loss) for 2 years, with the latest figure at $1159.0 in Q2 2025.
- Quarterly Investment Gain (Loss) changed N/A year-over-year to $1159.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $9786.0 (changed N/A YoY) and the FY2024 annual result came in at $6182.0, changed N/A from the prior year.
- Investment Gain (Loss) retreated to $1159.0 in Q2 2025 per BBOT's latest filing, from $2445.0 in the prior quarter.
- Over five years, Investment Gain (Loss) peaked at $3182.0 in Q4 2024 and troughed at $1159.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Investment Gain (Loss) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | - |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | - |
| 10 | BridgeBio Oncology Therapeutics | 719.69 Mn | 493.97 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 1,159.00 |
| Mar 31, 2025 | 2,445.00 |
| Dec 31, 2024 | 3,182.00 |
| Sep 30, 2024 | 3,000.00 |